• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Competitor Analysis: B7 – CD28/CTLA-4 Pathway Product Image

Competitor Analysis: B7 – CD28/CTLA-4 Pathway

  • ID: 2167840
  • July 2012
  • 35 Pages
  • La Merie Publishing


  • Amgen
  • AstraZeneca (MedImmune)
  • Boryung Pharmaceuticals
  • Compugen
  • Effimune
  • GlaxoSmithKline
  • MORE

The present Competitive Intelligence Report about the B7 – CD28/CTLA-4 signaling pathway provides a competitor evaluation in the field of antibodies and fusion proteins targeting the B7 – CD28/CTLA-4 pathway for treatment of autoimmune diseases or cancer as of July 2012.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies, fusion proteins and binding proteins which target members of the B7 – CD28/CTLA-4 signaling family to treat autoimmune diseases or cancer. In addition, the report lists company-specific R&D pipelines of projects in the B7 – CD28/CTLA-4 pathway.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


  • Amgen
  • AstraZeneca (MedImmune)
  • Boryung Pharmaceuticals
  • Compugen
  • Effimune
  • GlaxoSmithKline
  • MORE

- CTLA-4: Ipilimumab Pipeline
- CTLA-4: Others
- CD80/CD86 (B7.1/B7.2): Abatacept Pipeline
- CD80/CD86 (B7.1/B7.2): Others
- CD28
- B7/CD28 Pathway
- Programmed Death 1 (PD-1) Antagonists
- PD-1 Ligand (PD-L1) Inhibitors
- ICOS Antagonists
- B7-H3 Inhibitors
- Corporate B7 – CD28/CTLA-4 Pathway Inhibitor R&D Pipelines

- Amgen
- Astellas Pharma
- AstraZeneca (MedImmune)
- Atox Bio
- Boryung Pharmaceuticals
- Bristol-Myers Squibb
- Compugen
- CureTech
- Effimune
- Emergent BioSolutions
- GlaxoSmithKline
- Japan Tobacco
- KAHR Medical
- MacroGenics
- Merck Ono Pharmaceutical
- Roche (Genentech)
- Servier
- Teva Pharmaceutical Industries

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos